Table 3.

Distribution of IPD incidence by vaccine type pre-, and post-marketing introduction among the general and elderly populations in Spain

IPD vaccine type	Year of introduction of the vaccine	Period	Ns	Nr	Incidence (cases per 100.000)	95%CI
≥ 18 years
PCV7	2001	Pre	4	6	8.00	3.73– 17.18
		Post	12	40	2.85	2.06– 3.94
PCV13	2010	Pre	7	14	10.45	7.12– 15.32
		Post	6	15	4.92	3.17– 7.64
Non-PCV13	2010	Pre	4	9	5.25	3.16– 8.74
		Post	5	13	6.79	4.15– 11.12
≥ 60 years or ≥ 65 years
PCV7	2001	Pre	3	3	19.10	17.69– 20.62
		Post	10	21	5.50	3.84– 7.86
PCV13	2010	Pre	6	8	17.10	13.64– 22.96
		Post	6	8	9.55	6.97– 13.09
Non-PCV13	2010	Pre	4	5	9.63	7.18– 12.91
		Post	5	7	14.04	10.41– 18.94

PCV7: hepta-valent pneumococcal conjugate     Pre: pre-vaccine introduction period

PCV13: thirteen-valent pneumococcal conjugatePost: post-vaccine introduction period

Non-PCV13: non-thirteen-valent pneumococcal conjugate vaccine type     Ns: number of studies; Nr: number of records